Abbisko Cayman Past Earnings Performance
Past criteria checks 0/6
Abbisko Cayman has been growing earnings at an average annual rate of 17.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 2509% per year.
Key information
17.5%
Earnings growth rate
90.1%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 2,509.0% |
| Return on equity | -0.8% |
| Net Margin | -3.3% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Abbisko Cayman makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 497 | -16 | 91 | 444 |
| 31 Mar 24 | 258 | -224 | 94 | 439 |
| 31 Dec 23 | 19 | -432 | 96 | 434 |
| 30 Sep 23 | 19 | -457 | 102 | 429 |
| 30 Jun 23 | 19 | -483 | 108 | 424 |
| 31 Mar 23 | 10 | -489 | 113 | 402 |
| 31 Dec 22 | 0 | -496 | 118 | 379 |
| 30 Sep 22 | 11 | -1,075 | 129 | 342 |
| 30 Jun 22 | 23 | -1,654 | 140 | 306 |
| 31 Mar 22 | 23 | -1,797 | 144 | 268 |
| 31 Dec 21 | 23 | -1,810 | 125 | 226 |
| 31 Mar 21 | 7 | -774 | 26 | 155 |
| 31 Dec 20 | 0 | -707 | 21 | 133 |
| 31 Dec 19 | 4 | -134 | 22 | 81 |
Quality Earnings: 8ZD is currently unprofitable.
Growing Profit Margin: 8ZD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8ZD is unprofitable, but has reduced losses over the past 5 years at a rate of 17.5% per year.
Accelerating Growth: Unable to compare 8ZD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 8ZD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 8ZD has a negative Return on Equity (-0.76%), as it is currently unprofitable.